Solid Biosciences is trading 13.11% up at $9.49 after investors continued reacting to its August 6, 2026, second-quarter report and pipeline update.
- Q2 EPS of -$0.38 beat the -$0.46 consensus estimate
- SGT-003 was generally well tolerated among 53 participants in the Phase 1/2 trial
- Cash and securities of $377.7 million support operations into mid-2028